Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
LAA occlusion effectively reduces risk of stroke in patients with A-fib

LAA occlusion effectively reduces risk of stroke in patients with A-fib

CardioFocus’ HeartLight EAS to be highlighted at Heart Rhythm 2012

CardioFocus’ HeartLight EAS to be highlighted at Heart Rhythm 2012

Aspirin versus warfarin for heart failure patients

Aspirin versus warfarin for heart failure patients

Comorbidities common among patients with COPD

Comorbidities common among patients with COPD

Topera Medical to showcase RhythmView system at HRS annual meeting

Topera Medical to showcase RhythmView system at HRS annual meeting

AtriCure first quarter revenue increases 11.8% to $17.5 million

AtriCure first quarter revenue increases 11.8% to $17.5 million

Heart Rhythm Society launches Boston Citywide Awareness Campaign

Heart Rhythm Society launches Boston Citywide Awareness Campaign

EuroPRevent2012 to take place from May 3-5 in Dublin

EuroPRevent2012 to take place from May 3-5 in Dublin

Abbott, St. Jude Medical enter multi-year joint initiative for cardiovascular treatment technologies

Abbott, St. Jude Medical enter multi-year joint initiative for cardiovascular treatment technologies

Study finds under-treatment of RHD in India, Africa

Study finds under-treatment of RHD in India, Africa

Boston Scientific launches Z Flex-270 Steerable Sheath in the U.S.

Boston Scientific launches Z Flex-270 Steerable Sheath in the U.S.

Estech receives FDA IDE approval to initiate enrollment in TCRF ablation trial for AF

Estech receives FDA IDE approval to initiate enrollment in TCRF ablation trial for AF

Researchers identify genetic causes in nearly 1 in 5 patients with dilated cardiomyopathy

Researchers identify genetic causes in nearly 1 in 5 patients with dilated cardiomyopathy

Rivaroxaban found safe and effective in pulmonary embolism

Rivaroxaban found safe and effective in pulmonary embolism

CRT-D appropriate for patients with left ventricular dysfunction

CRT-D appropriate for patients with left ventricular dysfunction

CardioFocus introduces HeartLight Endoscopic Ablation System for AF in the Netherlands

CardioFocus introduces HeartLight Endoscopic Ablation System for AF in the Netherlands

Heart Failure Congress 2012 to take place from May 19-22

Heart Failure Congress 2012 to take place from May 19-22

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

Positive data from XENTION's XEN-D0103 phase 1 trial on AF

CJC publishes updated atrial fibrillation guidelines

CJC publishes updated atrial fibrillation guidelines

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.